|
General |
Study Status |
Completed |
Application Number / Requirement Number |
P040036 / PAS001 |
Date Original Protocol Accepted |
08/11/2006
|
Date Current Protocol Accepted |
08/11/2006
|
Study Name |
NaviStar Study
|
Device Name |
NAVISTAR THERMOCOOL DEFLECTABLE DIAGNOSTIC/ABLATION CATHETER
|
General Study Protocol Parameters |
Study Design |
Prospective Cohort Study
|
Data Source |
New Data Collection
|
Comparison Group |
Objective Performance Criterion
|
Analysis Type |
Analytical
|
Study Population |
Transit. Adolescent B (as adults) : 18-21 yrs,
Adult: >21
|
Detailed Study Protocol Parameters |
Study Objectives |
This is a prospective, observational, multi-site, non-randomized, single arm study (please expand). This study is designed to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease.
|
Study Population |
All patients who are considered for a radio frequency ablation procedure for drug refractory sustained, monomorphic or incessant ventricular tachycardia associated with coronary artery disease and who are eligible for treatment by a study investigator are to be screened, and then included in the study if they meet the inclusion and exclusion criteria.
|
Sample Size |
249 total subjects and 224 evaluable subjects, 18 sites
|
Key Study Endpoints |
Endpoints include: 1) One-year all cause mortality, 2) Cardiovascular-specific adverse event at one week, 3) cardiac perforation, 4) pericardial effusion with hemodynamic compromise, 5) pulmonary embolus, 6) complete heart block, 7) stroke, 8) acute myocardial infarction, 9) new acute severe mitral or aortic regurgitation, 10) deep venous thrombosis, arterial dissection or injury that requires surgical treatment, and 11) death.
|
Follow-up Visits and Length of Follow-up |
Follow-up period will be three years, with follow-up visits every 6 months.
|